1. Home
  2. ISSC vs CBIO Comparison

ISSC vs CBIO Comparison

Compare ISSC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Solutions and Support Inc.

ISSC

Innovative Solutions and Support Inc.

HOLD

Current Price

$19.35

Market Cap

167.7M

Sector

Technology

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$12.19

Market Cap

198.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISSC
CBIO
Founded
1988
2003
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
167.7M
198.9M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
ISSC
CBIO
Price
$19.35
$12.19
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$16.50
$25.60
AVG Volume (30 Days)
603.4K
233.3K
Earning Date
12-18-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
120.00
N/A
EPS
0.88
N/A
Revenue
$84,296,889.00
N/A
Revenue This Year
$7.03
N/A
Revenue Next Year
$4.17
N/A
P/E Ratio
$22.05
N/A
Revenue Growth
78.60
N/A
52 Week Low
$5.30
$9.81
52 Week High
$20.39
$21.40

Technical Indicators

Market Signals
Indicator
ISSC
CBIO
Relative Strength Index (RSI) 84.89 41.72
Support Level $10.94 $11.57
Resistance Level $20.39 $12.56
Average True Range (ATR) 1.13 0.98
MACD 0.86 -0.17
Stochastic Oscillator 88.98 13.73

Price Performance

Historical Comparison
ISSC
CBIO

About ISSC Innovative Solutions and Support Inc.

Innovative Solutions and Support Inc is a systems integrator that designs, manufactures, sells, and services air data equipment, engine display systems, standby equipment, primary flight guidance, and cockpit display systems for retrofit applications and original equipment manufacturers. The company supplies integrated Flight Management Systems, Flat Panel Display Systems, Integrated Standby Units, Positioning System receivers that enable reduced carbon footprint navigation, and an Autothrottle, which allows a pilot to automatically control the power setting of the engine and is designed to reduce pilot workload and enhance safety. It sells its products to both the OEM and the retrofit markets.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: